Loading clinical trials...
Loading clinical trials...
A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model
Conditions
Interventions
TL-925
Placebo
Locations
1
United States
Telios Investigative Site
Memphis, Tennessee, United States
Start Date
October 3, 2024
Primary Completion Date
December 10, 2024
Completion Date
December 10, 2024
Last Updated
November 13, 2024
NCT05839938
NCT05186025
NCT06602726
NCT05191186
NCT06800274
NCT06459219
Lead Sponsor
Telios Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions